Dividend Power Score
A single, comprehensive score designed to measure the true strength of a company’s dividend.
This score combines three essential pillars of dividend quality:
Consistency – Measures how reliable the dividend has been over time, focusing on payment history, stability, and the absence of cuts or suspensions.
Payability – Assesses the company’s financial ability to sustain its dividend, taking into account cash flow, earnings coverage, balance sheet strength, and overall financial health.
Growth – Evaluates the long-term growth of both the dividend and the company’s share price, highlighting businesses that consistently increase payouts while creating shareholder value.
Higher scores identify companies that have historically delivered dependable income alongside sustained dividend growth and long-term capital appreciation.
Company Overview
Solventum Corporation is a global healthcare company focused on developing and commercializing medical technologies, solutions, and services that improve patient outcomes and healthcare efficiency. The company operates primarily within the healthcare technology and medical products industry, serving providers, payers, and healthcare systems. Solventum’s core offerings span medical-surgical products, dental solutions, health information systems, and advanced purification and filtration technologies used in biopharmaceutical and medical applications.
The company’s primary revenue drivers include consumable medical products, capital equipment, and software-enabled solutions sold to hospitals, dental practices, laboratories, and life sciences customers. Solventum positions itself as a science- and innovation-driven organization with strong intellectual property and long-standing customer relationships, particularly in regulated healthcare markets. The company was formed in 2024 through the spin-off of 3M Health Care from 3M Company, creating an independent, publicly traded entity focused exclusively on healthcare growth and innovation.
Business Operations
Solventum generates revenue through four primary business segments: Medical Surgical, Dental Solutions, Health Information Systems, and Purification & Filtration. The Medical Surgical segment provides wound care, infection prevention, and surgical solutions used in hospitals and outpatient settings. Dental Solutions includes orthodontic products, restorative solutions, and digital dentistry technologies sold to dental professionals globally.
The Health Information Systems segment offers software and analytics platforms that support clinical documentation, revenue cycle management, and healthcare data integrity, primarily serving hospitals and payers. The Purification & Filtration segment supplies filtration and separation technologies used in biopharmaceutical manufacturing, medical devices, and laboratory environments. Solventum operates both domestically and internationally, leveraging proprietary technologies, manufacturing facilities, and distribution networks inherited from its former parent, 3M, while maintaining commercial and supply agreements that ensure operational continuity following the spin-off.
Strategic Position & Investments
Solventum’s strategic direction centers on accelerating organic growth, expanding margins, and increasing investment in high-growth healthcare markets such as biopharmaceutical filtration, digital health, and advanced wound care. The company emphasizes disciplined capital allocation, research and development investment, and operational efficiency as core strategic priorities following its separation from 3M.
The company continues to invest in innovation across its core segments, with a particular focus on software-enabled healthcare solutions and consumable products that generate recurring revenue. Solventum also maintains a portfolio of subsidiaries aligned with its operating segments, many of which were established under 3M’s healthcare division. Public disclosures indicate that, as of available filings, the company has not announced transformative acquisitions post-spin, and information on future acquisition plans remains limited; data inconclusive based on available public sources.
Geographic Footprint
Solventum is headquartered in the United States and operates globally across North America, Europe, Asia-Pacific, Latin America, and the Middle East & Africa. The company maintains manufacturing facilities, research centers, and commercial operations across multiple continents, supporting a diversified revenue base and reducing dependence on any single regional market.
International markets represent a significant portion of Solventum’s revenue, particularly in developed healthcare systems in Western Europe and Japan, as well as faster-growing markets in China, India, and Southeast Asia. The company’s global footprint reflects its strategy to serve multinational healthcare providers and life sciences companies while adapting products to local regulatory and clinical requirements.
Leadership & Governance
Solventum is led by an executive team with deep experience in healthcare, technology, and global operations, many of whom previously held senior leadership roles within 3M’s healthcare business. The leadership team emphasizes a strategic vision centered on innovation, customer-centric solutions, and long-term value creation as an independent healthcare company.
Key executives include:
- Bryan Hanson – Chief Executive Officer
- Theresa E. Jorgensen – Chief Financial Officer
- Jared Friedman – President, Health Information Systems
- Amit Sinha – President, Medical Surgical
- Chris Barry – President, Dental Solutions
The company is governed by a board of directors responsible for overseeing strategy, risk management, and corporate governance, with an emphasis on regulatory compliance, ethical conduct, and sustainable growth in global healthcare markets.